| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-60 |
Sentence |
denotes |
Approach to the Patient with COVID-19-Associated Thrombosis: |
| T2 |
61-81 |
Sentence |
denotes |
A Case-Based Review. |
| T3 |
82-190 |
Sentence |
denotes |
Coronavirus disease 2019 (COVID-19) is a current global pandemic caused by the novel coronavirus SARS-CoV-2. |
| T4 |
191-460 |
Sentence |
denotes |
Alongside its potential to cause severe respiratory illness, studies have reported a distinct COVID-19-associated coagulopathy that is characterized by elevated D-dimer levels, hyperfibrinogenemia, mild thrombocytopenia, and slight prolongation of the prothrombin time. |
| T5 |
461-707 |
Sentence |
denotes |
Studies have also reported increased rates of thromboembolism in patients with COVID-19, but variations in study methodologies, patient populations, and anticoagulation strategies make it challenging to distill implications for clinical practice. |
| T6 |
708-881 |
Sentence |
denotes |
Here, we present a practical review of current literature and uses a case-based format to discuss the diagnostic approach and management of COVID-19-associated coagulopathy. |
| T7 |
882-908 |
Sentence |
denotes |
IMPLICATIONS FOR PRACTICE: |
| T8 |
909-1074 |
Sentence |
denotes |
Coronavirus disease 2019 (COVID-19)-associated coagulopathy is characterized by elevated D-dimer levels, hyperfibrinogenemia, and increased rates of thromboembolism. |
| T9 |
1075-1199 |
Sentence |
denotes |
Current management guidelines are based on limited evidence from retrospective studies that should be interpreted carefully. |
| T10 |
1200-1489 |
Sentence |
denotes |
At this time, all hospitalized patients with suspected or confirmed COVID-19 should receive coagulation test surveillance and standard doses of prophylactic anticoagulation until prospective randomized controlled trials yield definitive information in support of higher prophylactic doses. |
